Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade,resulting in better control of infection and clinical outcomes;however,drug-drug interactions remain a significan...Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade,resulting in better control of infection and clinical outcomes;however,drug-drug interactions remain a significant hazard.Joint recommendations from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America regarding drug-drug interactions between HIV antiretroviral agents and direct-acting antiviral agents for treatment of hepatitis C virus (HCV) infection are reviewed here.This review is oriented to facilitate appropriate selection of an antiviral therapy regimen for HCV infection based on the choice of antiretroviral therapy being administered and,if necessary,switching antiretroviral regimens.展开更多
Chronic hepatitis C virus (HCV) infection has historically been difficult to treat in the HIV-infected population,owing to generally poor responses to interferon-based therapies.The recent rapid development of directl...Chronic hepatitis C virus (HCV) infection has historically been difficult to treat in the HIV-infected population,owing to generally poor responses to interferon-based therapies.The recent rapid development of directly acting antiviral agents (DAAs) against HCV has the potential to revolutionize treatment of this infection in the HIV population by improving tolerability and outcome,and,ultimately,reducing the significant burden of liver-related morbidity and mortality in this population.Clinical trials to address the safety and efficacy of novel DAAs in the HCV/HIV coinfected population are ongoing,and show much promise.The rapidity of current drug discovery in the field of HCV is both impressive and daunting for clinicians who will have to master these drugs.Going forward,the inclusion of individuals from this large and growing patient population in clinical trials will be of paramount importance.展开更多
文摘Therapy for human immunodeficiency virus (HIV) and chronic hepatitis C has evolved over the past decade,resulting in better control of infection and clinical outcomes;however,drug-drug interactions remain a significant hazard.Joint recommendations from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America regarding drug-drug interactions between HIV antiretroviral agents and direct-acting antiviral agents for treatment of hepatitis C virus (HCV) infection are reviewed here.This review is oriented to facilitate appropriate selection of an antiviral therapy regimen for HCV infection based on the choice of antiretroviral therapy being administered and,if necessary,switching antiretroviral regimens.
文摘Chronic hepatitis C virus (HCV) infection has historically been difficult to treat in the HIV-infected population,owing to generally poor responses to interferon-based therapies.The recent rapid development of directly acting antiviral agents (DAAs) against HCV has the potential to revolutionize treatment of this infection in the HIV population by improving tolerability and outcome,and,ultimately,reducing the significant burden of liver-related morbidity and mortality in this population.Clinical trials to address the safety and efficacy of novel DAAs in the HCV/HIV coinfected population are ongoing,and show much promise.The rapidity of current drug discovery in the field of HCV is both impressive and daunting for clinicians who will have to master these drugs.Going forward,the inclusion of individuals from this large and growing patient population in clinical trials will be of paramount importance.
